KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Adaptive Biotechnologies (ADPT) Accumulated Depreciation & Amortization (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $95.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 9.07% to $95.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $95.8 million through Dec 2025, up 9.07% year-over-year, with the annual reading at $95.8 million for FY2025, 9.07% up from the prior year.
  • Accumulated Depreciation & Amortization hit $95.8 million in Q4 2025 for Adaptive Biotechnologies, up from $87.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $95.8 million in Q4 2025 to a low of $36.2 million in Q4 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $69.5 million across 5 years, with a median of $73.2 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 50.03% in 2022 and later grew 9.07% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $36.2 million in 2021, then skyrocketed by 50.03% to $54.4 million in 2022, then surged by 34.75% to $73.2 million in 2023, then rose by 19.91% to $87.8 million in 2024, then rose by 9.07% to $95.8 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ADPT at $95.8 million in Q4 2025, $87.8 million in Q4 2024, and $73.2 million in Q4 2023.